


*a<sup>2</sup> with*  
sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq.

I.D. No. 3;

and  $Q_1$  is an electronegative leaving group.

---

*a<sup>3</sup>*  
28. (Amended) A pharmaceutical composition comprising a physiologically acceptable carrier and a compound of the formula:



where Z is an N-terminal protecting group;


$Q_2$  is 0 to 4 amino acids such that  $Q_2$ -Asp substantially corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3;

and

$Q_1$  is an electronegative leaving group.

---

*a<sup>4</sup>*  
43. (Amended) A method of treating inflammation or treating an autoimmune disease in a mammal in need of such treatment comprising administering to said mammal an effective amount of a compound of the formula:



where Z is an N-terminal protecting group;

$Q_2$  is 0 to 4 amino acids such that the sequence  $Q_2$ -Asp substantially corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq.

I.D. No. 3; and

$Q_1$  is an electronegative leaving group.

---